CD73: A Promising Biomarker in Cancer Patients
Main Authors: | Roberta Turiello, Aldo Pinto, Silvana Morello |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.609931/full |
Similar Items
-
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
by: Jerry B. Harvey, et al.
Published: (2020-04-01) -
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
by: Silvana Morello, et al.
Published: (2017-12-01) -
Thrombo-Inflammation: A Focus on NTPDase1/CD39
by: Silvana Morello, et al.
Published: (2021-08-01) -
Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases
by: Dipti Vijayan, et al.
Published: (2017-05-01) -
Exacerbation of Allergic Airway Inflammation in Mice Lacking ECTO-5′-Nucleotidase (CD73)
by: Elisabetta Caiazzo, et al.
Published: (2020-11-01)